Mode
Text Size
Log in / Sign up

Meta-analysis shows no significant difference between immediate and staged revascularization for STEMI with multivessel diseaseImmediate heart procedure shows no major benefit over staged approach for heart attack patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that immediate revascularization does not significantly improve outcomes compared to staged revascularization in this patient population.

This systematic review and meta-analysis examined patients with ST-elevation myocardial infarction and multivessel disease to compare immediate versus staged complete revascularization strategies. The study population was predominantly male with an average age in the mid-sixties. Researchers assessed major adverse cardiovascular events along with all-cause mortality, recurrent myocardial infarction, and various safety endpoints including stroke and major bleeding.

The analysis found no significant difference in major adverse cardiovascular events between the two groups. Similarly, mortality rates and risks of recurrent myocardial infarction or unplanned revascularization were comparable regardless of the timing of the procedure. Safety outcomes such as stroke, major bleeding, and acute nephropathy were also observed to be similar between the immediate and staged approaches.

The authors noted heterogeneity across the included randomized controlled trials and acknowledged that some trials excluded left main disease or utilized intravascular imaging. While findings were consistent across sensitivity analyses, the presence of heterogeneity warrants caution. The practice relevance supports a revascularization approach that incorporates anatomic complexity, physiology, procedural logistics, and patient-specific factors when determining optimal timing.

A major review of 4,472 heart attack patients with multiple blocked arteries compared two treatment strategies. One group had the full artery-opening procedure done immediately, while the other had it done in stages over time. The study followed patients for about 18 months on average.

The main finding was that doing the full procedure immediately did not lower the chance of major heart problems like death, another heart attack, or needing more procedures. The risk was about the same for both groups. This was true for overall death, heart-related death, and repeat heart attacks.

Safety outcomes were also similar between the two approaches. The risks of stroke, major bleeding, and kidney problems from the procedure were comparable. The review included patients mostly in their mid-60s, and most were male.

The authors note some limitations, like differences between the included studies and the exclusion of patients with certain complex blockages. They suggest that the best timing for the procedure should consider the patient's specific situation, the artery anatomy, and hospital logistics.

In summary, for most heart attack patients with multiple blocked arteries, doing the full procedure immediately does not offer a clear advantage over waiting and doing it in stages.

What this means for you:
For heart attack patients with multiple blocked arteries, doing the full procedure immediately does not lower the risk of major heart problems compared to a staged approach.

Study Details

Study typeMeta analysis
Sample sizen = 4,472
EvidenceLevel 1
Follow-up18.5 mo
PublishedMay 2026
View Original Abstract ↓
Complete revascularization (CR) in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease (MVD) is recommended, but the timing of revascularization, either immediate or staged remains a topic of debate. A systematic search of MEDLINE, Scopus, and Cochrane databases was performed to identify randomized controlled trials (RCTs) that evaluated patients with STEMI and MVD and compared outcomes between immediate CR versus staged CR. The primary outcome was major adverse cardiovascular events. Eleven RCTs were included in this analysis with 4,472 patients assessed at a weighted mean follow-up of 18.5 months. Patients were 79% male with an average age of 64 years. Five RCTs utilized some degree of intravascular imaging or physiology, 7 RCTs explicitly excluded left main (LM) disease, and 6 RCTs exclusively utilized drug-eluting stents (DES). Compared to staged CR, immediate CR did not significantly reduce the incidence of major adverse cardiovascular events (risk ratios [RR] 0.92 [0.73, 1.17]), all-cause mortality (RR 1.31 [0.97, 1.78]), cardiovascular mortality (RR 1.28 [0.87, 1.90]), recurrent myocardial infarction (MI) (RR 0.78 [0.57, 1.07]), unplanned revascularization (RR 0.87 [0.67, 1.14]), or stent thrombosis (RR 1.39 [0.79, 2.43]). Safety endpoints were comparable between both groups: stroke (RR 0.91 [0.51, 1.62]), major bleeding (RR 0.76 [0.49, 1.18]), and acute nephropathy (RR 0.88 [0.59, 1.31]). Sensitivity analysis demonstrated consistent findings regarding the primary outcome across all scenarios. Immediate and staged CR demonstrated similar efficacy and safety. In conclusion, these neutral findings were consistent despite heterogeneity across RCTs, and support a revascularization approach incorporating anatomic complexity, physiology, procedural logistics, and patient-specific factors when determining the optimal timing of CR in patients with STEMI and MVD.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.